| Literature DB >> 28704654 |
Donal McHugh1, Nicole Caduff1, Mario Henrique M Barros2, Patrick C Rämer1, Ana Raykova1, Anita Murer1, Vanessa Landtwing1, Isaak Quast3, Christine T Styles4, Michael Spohn5, Adeola Fowotade6, Henri-Jacques Delecluse7, Alexandra Papoudou-Bai8, Yong-Moon Lee9, Jin-Man Kim9, Jaap Middeldorp10, Thomas F Schulz11, Ethel Cesarman12, Andrea Zbinden13, Riccarda Capaul13, Robert E White4, Martin J Allday4, Gerald Niedobitek2, David J Blackbourn6, Adam Grundhoff5, Christian Münz14.
Abstract
The human tumor viruses Epstein-Barr virus (EBV) and Kaposi sarcoma-associated herpesvirus (KSHV) establish persistent infections in B cells. KSHV is linked to primary effusion lymphoma (PEL), and 90% of PELs also contain EBV. Studies on persistent KSHV infection in vivo and the role of EBV co-infection in PEL development have been hampered by the absence of small animal models. We developed mice reconstituted with human immune system components as a model for KSHV infection and find that EBV/KSHV dual infection enhanced KSHV persistence and tumorigenesis. Dual-infected cells displayed a plasma cell-like gene expression pattern similar to PELs. KSHV persisted in EBV-transformed B cells and was associated with lytic EBV gene expression, resulting in increased tumor formation. Evidence of elevated lytic EBV replication was also found in EBV/KSHV dually infected lymphoproliferative disorders in humans. Our data suggest that KSHV augments EBV-associated tumorigenesis via stimulation of lytic EBV replication.Entities:
Keywords: B cell lymphoma; EBV; Epstein-Barr virus; KSHV; Kaposi sarcoma-associated herpesvirus; humanized mouse model; lytic EBV replication; primary effusion lymphoma; virus-associated lymphoma
Mesh:
Substances:
Year: 2017 PMID: 28704654 DOI: 10.1016/j.chom.2017.06.009
Source DB: PubMed Journal: Cell Host Microbe ISSN: 1931-3128 Impact factor: 21.023